Gene therapy (Adenoviral vector) · Gene-mediated cytotoxicity · developed by Candel Therapeutics
Aglatimagene besadenovec is an adenoviral vector expressing herpes simplex virus thymidine kinase (HSV-tk) that sensitizes tumor cells to the prodrug valacyclovir or ganciclovir, leading to selective tumor cell death. It is studied in prostate cancer, glioma, lung cancer, mesothelioma, breast cancer, and ovarian cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07660094 | Phase 3 | Non-squamous, Non-Small Cell Lung Cancer | Recruiting | CADL |
| NCT01436968 | Phase 3 | Prostate Cancer | Active not recruiting | CADL |
| NCT00589875 | Phase 2 | Malignant Glioma | Completed | CADL |
| NCT03576612 | Phase 1 | Glioma, Malignant | Completed | CADL |
| NCT03131037 | Phase 1 | Lung Cancer | Completed | CADL |
| NCT01997190 | Phase 1 | Malignant Pleural Effusion | Completed | CADL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Non-squamous, Non-Small Cell Lung CancerProstate CancerAnaplastic AstrocytomaBreast CancerGlioblastoma MultiformeGlioma, MalignantHigh Grade GliomaLung CancerMalignant GliomaMalignant Pleural EffusionMesotheliomaOvarian Cancer
Updated Oct 3, 2026. Something wrong or missing? Report it on the CADL page.
See CADL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CADL catalysts and pipeline →